Israeli biotechnology company Medison Pharma has signed an agreementwith AltaRex Corp to establish a 50:50 joint venture to commercialize OvaRex MAb for the treatment of ovarian cancer and other oncology products in Israel and the Middle East.
AltaRex estimates that in the region covered by the JV, OvaRex alone represents potential sales of some $5 million annually. Medison currently markets products in the region for firms such as Biogen, Sangstat, Beaufour Ipsen, Nycomed Amersham and Antigenics.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze